Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA.

Image 0 of Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA.Image 1 of Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA.Image 2 of Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA.

Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA.

Call for Price

Fluocinonide 0.05% Cream 120 Gm By Taro Pharmaceuticals USA. This item requires a valid order from a physician licensed in the USA. Item No.:RXD2046209/RXB10024694
Size : 120 GM
Selling UoM : EA
NDC: 51672-1253-04
UPC Barcode :
Supplier: 0050000602 TARO PHARMACEUTICALS
Supplier Material : 125304
Generic Code : 007616 FLUOCINONIDE TOPICAL CREAM (G) 0.05 %
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generic RX

Have a question?

  Call for Price

Compares To: Lidex-E? and Lidex?

LIDEX
(fluocinonide) Cream

DRUG DESCRIPTION
LIDEX (fluocinonide) Cream 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-.

LIDEX Cream contains fluocinonide 0.5 mg/g in FAPG? cream, a specially formulated cream base consisting of citric acid, 1,2,6-hexanetriol, polyethylene glycol 8000, propylene glycol and stearyl alcohol. This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophylic properties. In this formulation, the active ingredient is totally in solution.

INDICATIONS

LIDEX Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DOSAGE AND ADMINISTRATION

LIDEX Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

SIDE EFFECTS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning
Itching
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions Hypopigmentation Perioral dermatitis
Allergic contact dermatitis Maceration of the skin
Secondary infection
Skin atrophy
Striae
Miliaria

PRECAUTIONS
General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.